je.st

Home › lillys

Tag: lillys

Lilly's CYRAMZA (ramucirumab) Receives Fourth FDA Approval

2015-04-27 05:33:40| drugdiscoveryonline Home Page

Eli Lilly and Company (NYSE: LLY) has received its fourth U.S. Food and Drug Administration (FDA) approval for CYRAMZA® (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

Tags: fourth approval receives fda

Rexahn's Lead Drug RX-3117 Beats Lilly's Gemzar In One-To-One Face Off

2015-01-14 09:33:23| Biotech - Topix.net

New peer-reviewed scientific data from Rexahn is testimony to sound evidence of tumor shrinkage versus popular but problematic Gemzar. Risks include early data that may not translate in larger study results, possible funding needs, regulatory hurdles, and competition for more well-capitalized players.

Tags: off face lead drug

Eli Lilly's Cyramza gets new marketing approval

2014-12-12 22:42:55| Biotech - Topix.net

The Food and Drug Administration is allowing Lilly to market the drug as a treatment for cases that have spread. Earlier this year the FDA approved the drug as a treatment for gastric cancer.

Tags: marketing approval eli lillys

EU OKs Eli Lilly's $5.4B bid for Novartis division

2014-10-04 01:05:37| Biotech - Topix.net

The European Union's antitrust authority says it has approved the $5.4 billion sale of Novartis' animal health division to U.S. pharmaceutical firm Eli Lilly. The 28-nation bloc's executive Commission said Friday the sale won't hinder competition because the merged firm will continue to face a number of strong competitors.

Tags: division bid eli novartis